Biofrontera Inc (BFRI NASDAQ) stock market data APIs
$0.6954
0.02(2.9%)
as of July 3, 2025
Try our APIs with
free plan!
Biofrontera Inc Financial Data Overview
Price chart is built with
Anychart
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Prev. Close
0.6954
Open
0.7138
High
0.7242
Low
0.6944
52 wk Range
0.536-1.54
Market Cap
6 612 K
Shares Outstanding
9 446 K
Revenue
37 997 K
EPS
-0.5084
Beta
0.299
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biofrontera Inc data using free add-ons & libraries
Get Biofrontera Inc Fundamental Data
Biofrontera Inc Fundamental data includes:
- Net Revenue: 37 997 K
- EBITDA: -15 968 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.29
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biofrontera Inc News
New
Biofrontera restructures relationship with Biofrontera AG, backed by $11M investment
Biofrontera (NASDAQ:BFRI [https://seekingalpha.com/symbol/BFRI]) said on Monday that it has acquired [https://seekingalpha.com/pr/20151642-biofrontera-inc-announces-major-restructuring-of-relationship...
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
WOBURN, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms...
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.The Orange Book is published by the U.S. Food and Drug ...
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update
Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
